Biologic nanoparticles and platelet reactivity

Nanomedicine

Volumn 4, Issue 7, 2009, Pages 725-733

  Miller, Virginia M ^a   Hunter, Larry W ^a   Chu, Kevin ^a   Kaul, Vivasvat ^a   Squillace, Phillip D ^a   Lieske, John C ^a   Jayachandran, Muthuvel ^a  

^a MAYO CLINIC   (United States)

Author keywords

ATP secretion; Calcium phosphate; Dense granules; Fetuin; Platelet aggregation; Protein mineral complexes; Thrombin

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM PHOSPHATE; CONVULXIN; HYDROXYAPATITE; INDOMETACIN; N(G) METHYLARGININE; NANOPARTICLE; THROMBIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ANTICOAGULATION; ARTICLE; CELL GRANULE; CONTROLLED STUDY; HUMAN; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN SECRETION; RABBIT; THROMBOCYTE; THROMBOCYTE AGGREGATION; TURBIDITY;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; ANIMALS; BIOCOMPATIBLE MATERIALS; CATTLE; DURAPATITE; FEMALE; HUMANS; MALE; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; MICROSCOPY, SCANNING TUNNELING; MIDDLE AGED; NANOMEDICINE; NANOPARTICLES; PLATELET AGGREGATION; PLATELET-RICH PLASMA; RABBITS;

EID: 73349115751     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.09.61     Document Type: Article

References (41)

1. Leroyer AS, Isobe H, Leseche G et al.: Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J. Am. Coll. Cardiol. 49(7), 772-777 (2007).
2. Jayachandran M, Litwiller RD, Owen WG et al.: Characterization of blood borne microparticles as markers of premature coronary calcification in recently menopausal women. Am. J. Physiol. Heart Circ. Physiol. 295, 931-938 (2008). • Identification of different populations of nano/microsized particles in persons with asymptomatic coronary calcification.
3. Toth B, Liebhardt S, Steinig K et al.: Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb. Haemost. 100(4), 663-669 (2008).
4. Piccin A, Murphy WG, Smith OP: Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 21(3), 157-171 (2007). •• Excellent review of the issues related to the clinical implications of bloodborne nano/microsized particles as diagnostic and prognostic markers.
5. Miller VM, Rodgers G, Charlesworth JA et al.: Evidence of nanobacterial-like structures in human calcified arteries and cardiac valves. Am. J. Physiol. Heart Circ. Physiol. 287, H1115-H1124 (2004).
6. Amabile N, Guerin AP, Leroyer A et al.: Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J. Am. Soc. Nephrol. 16(11), 3381-3388 (2005). • One of the first papers to identify nanosized particles in blood.
7. Akerman KK, Juronen I, Kajander EO: Scanning electron microscopy of nanobacteria - novel biofilm producing organisms in blood. Scan. Electron Microsc. 15(Suppl. 3), 90-91 (1993).
8. Ciftcioglu N, Bjorklund M, Kuorikoski K, Bergstrom K, Kajander EO: Nanobacteria: an infectious cause for kidney stone formation. Kidney Int. 56, 1893-1898 (1999).
9. Drancourt M, Jacomo V, Lepidi H et al.: Attempted isolation of Nanobacterium sp. microorganisms from upper urinary tract stones. J. Clin. Microbiol. 41, 368-372 (2003).
10. Hjelle JT, Miller-Hjelle MA, Poxton IR et al.: Endotoxin and nanobacteria in polycystic kidney disease. Kidney Int. 57, 2360-2374 (2000).
11. Sedivy R, Battistutti WB: Nanobacteria promote crystallization of psammoma bodies in ovarian cancer. APMIS 111, 951-954 (2003).
12. Cisar Jo, Xu D-Q, Thompson J, Swaim W, Hu L, Kopecko DJ: An alternative interpretation of nanobacteria-induced biomineralization. Proc. Natl Acad. Sci. USA 97, 11511-11515 (2000). • Openly spurred the controversy regarding the biochemical composition of nanoparticles contributing to formation of calcific biofilm.
13. Jelic TM, Malas AM, Groves SS et al.: Nanobacteria-caused mitral valve calciphylaxis in a man with diabetic renal failure. South Med. J. 97, 194-198 (2004).
14. Shoskes DA, Thomas KD, Gomez E: Anti-nanobacterial therapy for men with chronic prostatitis/chronic pelvic pain syndrome and prostatic stones: preliminary experience. J. Urol. 173, 474-477 (2005).
15. Schwartz Mk, Lieske JC, Hunter LW, Miller VM: Systemic injection of planktonic forms of mammalian-derived nanoparticles alters arterial response to injury in rabbits. Am. J. Physiol. Heart Circ. Physiol. 296, 1434-1441 (2009). •• Demonstrates differential in vivo pathogenic activity of nanoparticles of three different compositions.
16. Kumar V, Farell G, Yu S et al.: Cell biology of pathologic renal calcification: Contribution of crystal transcytosis, cell-mediated calcification, and nanoparticles. J. Investig. Med. 54(7), 412-424 (2006).
17. Benzerara K, Miller VM, Farell G et al.: Search for microbial signatures within human and microbial calcifications using soft-x-ray spectromicroscopy. J. Invest. Med. 54, 367-379 (2006).
18. Martel J, Ding-E Young J: Purported nanobacteria in human blood as calcium carbonate nanoparticles. Proc. Natl Acad. Sci. USA 105(14), 5549-5554 (2008).
19. Young JD, Martel J, Young L, Wu CY, Young A, Young D: Putative nanobacteria represent physiological remnants and culture by-products of normal calcium homeostasis. PLoS ONE 4(2), e4417 (2009). •• Description of biochemical manipulations of media that results in formation of calcific nanosized particles.
20. Raoult D, Drancourt M, Azza S et al.: Nanobacteria are mineralo fetuin complexes. PLoS Pathog. 4(2), e41 (2008).
21. Lieske JC, Norris R, Toback FG: Adhesion of hydroxyapatite crystals to anionic sites on the surface of renal epithelial cells. Am. J. Physiol. 273, F224-F233 (1997).
22. Schwartz Ma-K, Lieske JC, Kumar V, Farell-Baril G, Miller VM: Human-derived nanoparticles and vascular responses to injury in rabbit carotid arteries: proof of principle. Int. J. Nanomed. 3, 243-248 (2008).
23. Bucki R, Pastore JJ: Bacterial endotoxin as inhibitor of the enzymatic activity of human thrombin. Eur. J. Haematol. 76(6), 510-515 (2006).
24. Oberdorster G, Oberdorster E, Oberdorster J: Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 113, 823-839 (2005).
25. Donaldson K, Stone V: Current hypotheses on the mechanisms of toxicity of ultrafine particles. Ann. Ist. Super. Sanita 39, 405-410 (2003).
26. Vertegel AA, Siegel RW, Dordick JS: Silica nanoparticle size influences the structure and enzymatic activity of adsorbed lysozyme. Langmuir 20, 6800-6807 (2004).
27. Brown Dm, Stone V, Findlay P, Macnee W, Donaldson K: Increased inflammation and intracellular calcium caused by ultrafine carbon black is independent of transition metals or other soluble components. Occup. Environ. Med. 57, 684-691 (2000).
28. Radomski A, Jurasz P, Alonso-Escolano D et al.: Nanoparticle-induced platelet aggregation and vascular thrombosis. Br. J. Pharmacol. 146(6), 882-893 (2005). •• Detailed description of effects of diverse nanoparticles on platelet activation.
29. Ferraz N, Carlsson J, Hong J, Ott Mk: Influence of nanoporesize on platelet adhesion and activation. J. Mater. Sci. Mater. Med. 19, 3115-3121 (2008).
30. Ross R: Cell biology of atherosclerosis. Annu. Rev. Physiol. 57, 791-804 (1995).
31. Cejas MA, Chen C, Kinney WA, Maryanoff BE: Nanoparticles that display short collagen-related peptides. Potent stimulation of human platelet aggregation by triple helical motifs. Bioconjug. Chem. 18, 1025-1027 (2007).
32. Mayer A, Vadon M, Rinner B, Novak A, Wintersteiger R, Frohlich E: The role of nanoparticle size in hemocompatibility. Toxicology 258, 139-147 (2009).
33. Miyamoto M, Sasakawa S, Ozawa T, Kawaguchi H, Ohtsuka Y: Platelet aggregation induced by latex particles. Effects of size, surface potential and hydrophobicity of particles. Biomaterials 10, 251-257 (1989).
34. Koziara J, Oh J, Akers W, Ferraris S, Mumper R: Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles. Pharm. Res. 22, 1821-1828 (2005).
35. Nel A: Air pollution - related illness: effects of particles. Science 308, 804-806 (2005). •• Excellent summary of potential complex interactions of nanoparticles with biological tissue.
36. Wang G, Siggers K, Zhang S et al.: Preparation of bmp-2 containing bovine serum albumin (BSA) nanoparticles stabilized by polymer coating. Pharm. Res. 25, 2896-2909 (2008).
37. Balasundaram G, Sato M, Webster TJ: Using hydroxyapatite nanoparticles and decreased crystallinity to promote osteoblast adhesion similar to functionalizing with RGD. Biomaterials 27, 2798-2805 (2006).
38. Nahar M, Dutta T, Murugesan S et al.: Functional polymeric nanoparticles: an efficient and promising tool for active delivery of bioactives. Crit. Rev. Ther. Drug Carrier Syst. 23(4), 259-318 (2006).
39. Nahrendorf M, Zhang H, Hembrador S et al.: Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 117(3), 379-387 (2008).
40. Hugel B, Socie G, Vu T et al.: Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 93(10), 3451-3456 (1999).
41. Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM: Exploring the biology of vascular calcification in chronic kidney disease: what's circulating? Kidney Int. 73(4), 384-390 (2008).